CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
HB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss. These candidates promote nerve regeneration and protect against damage, offering a new approach to managing these conditions.
HB-086 and HB-097 comprise our portfolio of therapeutic proteins.
They are a family of growth factors with actions on sensory nerve cells and represent a novel treatment approaches and a paradigm shift for medical treatment and prevention of severe, chronic conditions as pain and hearing loss.
The drug candidates target sensory nerve cells and their support cells in dorsal root ganglia and inner ear.
Evidence indicate a mode of action including normalisation of impaired neuronal-glial crosstalk,…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
